CHONGQING FOCHON PHARMACEUTICAL CO LTD has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are REVIRAL LTD, UNIV DE DROIT ET DE LA SANTE DE LILLE 2 and CYTEIR THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Australia | 2 | |
#4 | Brazil | 2 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Mexico | 1 | |
#7 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Wang Weibo | 11 |
#2 | Sun Jing | 10 |
#3 | Zhao Xingdong | 10 |
#4 | Liu Qihong | 10 |
#5 | Tan Haohan | 9 |
#6 | Li Tongshuang | 9 |
#7 | Rong Yue | 9 |
#8 | Liu Bin | 8 |
#9 | Tan Rui | 8 |
#10 | Wang Xianlong | 7 |
Publication | Filing date | Title |
---|---|---|
WO2017121308A1 | Fused pyridine compounds, compositions and methods of use | |
WO2017114351A1 | Certain protein kinase inhibitors | |
CN108699027A | Indolizine analog derivative, composition and application method |